CELGENE CORPORATION

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: ACY-1215 in combination with pomalidomide and dexamethasone

First Posted Date: 2014-07-14

Last Posted Date: 2019-11-21

Lead Sponsor: Celgene

Target Recruit Count: 16

Registration Number: NCT02189343

Locations: 🇺🇸
CTRC at The UT Health Science Center at San Antonio, San Antonio, Texas, United States
🇺🇸
UT Southwestern Medical Center Simmons Comprehensive Cancer Center, Dallas, Texas, United States
🇺🇸
University of Utah Huntsman Cancer Institute, Salt Lake City, Utah, United States

A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.

Phase 2

Completed

Conditions: Systemic Lupus Erythematosus

Interventions: Drug: CC-220
Drug: Placebo

First Posted Date: 2014-07-09

Last Posted Date: 2020-03-19

Lead Sponsor: Celgene

Target Recruit Count: 42

Registration Number: NCT02185040

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Arizona Arthritis and Rheumatology Research, PLLC, Paradise Valley, Arizona, United States
🇺🇸
UCSD Center for Innovative Therapy, La Jolla, California, United States

and more 32 locations

Food Effect and CYP1A2 Induction Study in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Pomalidomide
Other: Caffeine
Other: Tobacco

First Posted Date: 2014-06-20

Last Posted Date: 2018-11-15

Lead Sponsor: Celgene

Target Recruit Count: 55

Registration Number: NCT02168205

Locations: 🇺🇸
Covance Clinical Research Unit, Daytona Beach, Florida, United States

A Post Authorisation Registry of IMNOVID (Pomalidomide) for Patients With Relapsed and Refractory Multiple Myeloma.

Completed

Conditions: Multiple Myeloma

Interventions: Drug: IMNOVID

First Posted Date: 2014-06-17

Last Posted Date: 2022-10-20

Lead Sponsor: Celgene

Target Recruit Count: 775

Registration Number: NCT02164955

Locations: 🇧🇪
Centre Hospitalier Peltzer-La Tourelle, Verviers, Rue Du Parc 29, Belgium
🇧🇪
Clinique Saint-Pierre, Ottignies, Belgium
🇬🇧
Broomfield Hospital, Broomfield,Chelmsford, Essex, United Kingdom

and more 119 locations

Validation of a Comprehensive Health Status Assessment Scale in Elderly Patients (≥ 65 Years) With Hematological Malignancies

Completed

Conditions: Multiple Myeloma
Leuklemia, Lymphocytic, Chronic
Myelodysplastic Syndromes
Leukemia Myeloid Acute

Interventions: Other: Geriatric Assessment of Health Status Scale administration

First Posted Date: 2014-06-16

Last Posted Date: 2019-11-18

Lead Sponsor: Celgene

Target Recruit Count: 363

Registration Number: NCT02164071

Locations: 🇪🇸
Hospital Txagorritxu, Vitoria, Alava, Spain
🇪🇸
Hospital Parc Tauli, Sabadell, Barcelona, Spain
🇪🇸
Hospital de Donostia, San Sebastian, Guipuzcoa, Spain

and more 19 locations

Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma

Phase 3

Withdrawn

Conditions: Multiple Myeloma
Neoplasms
Plasma Cells
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Therapeutic Uses

Interventions: Drug: Lenalidomide

First Posted Date: 2014-06-04

Last Posted Date: 2018-04-10

Lead Sponsor: Celgene

Registration Number: NCT02155634

Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly

Phase 4

Completed

Conditions: Squamous Cell Carcinoma
Adenocarcinoma
Carcinoma, Large Cell
Non-Small Cell Lung Cancer
Carcinoma
Lung Neoplasm

Interventions: Drug: nab-paclitaxel
Drug: Carboplatin

First Posted Date: 2014-05-30

Last Posted Date: 2018-09-24

Lead Sponsor: Celgene

Target Recruit Count: 143

Registration Number: NCT02151149

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Central Coast Medical Oncology Corporation, Santa Maria, California, United States
🇺🇸
Northshore University Healthsystem Research Institute, Evanston, Illinois, United States

and more 52 locations

Post Marketing Surveillance to Collect and Evaluate the Safety and Efficacy Information of Korean MDS Patients Treated With VIDAZA®, After Approval of Marketing Authorization for New Drug in Korea

Completed

Conditions: Myelodysplastic Syndrome

Interventions: Drug: Vidaza®

First Posted Date: 2014-05-14

Last Posted Date: 2019-11-18

Lead Sponsor: Celgene

Target Recruit Count: 511

Registration Number: NCT02137629

Locations: 🇰🇷
Dongnam Inst. of Radiological & Medical Science, Busan, Korea, Republic of
🇰🇷
Dong-a University Medical Center, Busan, Korea, Republic of
🇰🇷
Soon Chun Hyang University Hospital Cheonan, Cheonan, Korea, Republic of

and more 44 locations

A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab

Phase 1

Terminated

Conditions: Squamous Cell Carcinoma of the Head and Neck

Interventions: Drug: Motolimod
Drug: Cetuximab
Drug: Nivolumab

First Posted Date: 2014-04-28

Last Posted Date: 2019-10-25

Lead Sponsor: Celgene

Target Recruit Count: 18

Registration Number: NCT02124850

Locations: 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

Lenalidomide vs Placebo Maintenance Therapy Following Melphalan Prednisone Velcade® Induction Therapy in NDMM

Phase 3

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Lenalidomide

First Posted Date: 2014-04-11

Last Posted Date: 2021-04-14

Lead Sponsor: Celgene

Target Recruit Count: 46

Registration Number: NCT02112175

Locations: 🇫🇷
CHRU Hopital Claude Huriez, Lile Cedax, France
🇫🇷
Hopital Saint Louis, Paris, France
🇫🇷
CH Argenteuil Victor DupouyHematologie, Argenteuil, France

and more 70 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy